alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 63 studies with an author at The University of Queensland (AU) (page 1 of 3) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Delirium and incident dementia in hospital patients in New South Wales, Australia: retrospective cohort study

✓ Peer-reviewed alzhub usefulness score 72 out of 100. BMJ 2024-03-27

The study findings suggest delirium was a strong risk factor for death and incident dementia among older adult patients. 3 key findings →

Design: cohort Participants: 110,422 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Common Genetic Variation Indicates Separate Causes for Periventricular and Deep White Matter Hyperintensities

✓ Peer-reviewed alzhub usefulness score 71 out of 100. Stroke 2020-06-10

Periventricular white matter hyperintensities (WMH; PVWMH) and deep WMH (DWMH) are regional classifications of WMH and reflect proposed differences in cause. 4 key findings →

Design: meta-analysis Participants: 26,654 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Cerebral small vessel disease genomics and its implications across the lifespan

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Nature communications 2020-12-08

White matter hyperintensities (WMH) are the most common brain-imaging feature of cerebral small vessel disease (SVD), hypertension being the main known risk factor. 1 key finding →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The Association Between Gait Speed and Cognitive Status in Community-Dwelling Older People: A Systematic Review and Meta-analysis

✓ Peer-reviewed alzhub usefulness score 70 out of 100. The journals of gerontology. Series A, Biological sciences and medical sciences 2019-05-01

The strength of evidence for an association between gait speed and cognition was demonstrated by the number and consistency of results, as well as quality of the studies. 5 key findings →

Design: meta-analysis Participants: 29,520 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Effectiveness of an Internet intervention for family caregivers of people with dementia: results of a randomized controlled trial

✓ Peer-reviewed alzhub usefulness score 67 out of 100. PloS one 2015-02-13

The Internet course 'Mastery over Dementia' offers an effective treatment for family caregivers of people with dementia reducing symptoms of depression and anxiety. 4 key findings →

Participants: 149 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Maintain Your Brain: Protocol of a 3-Year Randomized Controlled Trial of a Personalized Multi-Modal Digital Health Intervention to Prevent Cognitive Decline Among Community Dwelling 55 to 77 Year Olds

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Journal of Alzheimer's disease : JAD 2019-01-01

MYB will be the largest internet-based trial to attempt to prevent cognitive decline and potentially dementia. 5 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Nature 1998-06-01

Thirteen families have been described with an autosomal dominantly inherited dementia named frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), historically termed Pick's disease. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Nature 2022-02-23

A hallmark pathological feature of the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) is the depletion of RNA-binding protein TDP-43 from the nucleus of neurons in the brain and spinal cord 1 . 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Antihypertensive drug classes and risk of incident dementia: a multinational population-based cohort study

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Age and Ageing 2025-04-28

One million nine hundred twenty-five thousand, five hundred sixty-three individuals were included across the four databases with a median follow-up ranging from 5.6 to 8.4 years. 4 key findings →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Delirium and adverse clinical outcomes: a matched cohort study in the UK Biobank

✓ Peer-reviewed alzhub usefulness score 62 out of 100. The Lancet Healthy Longevity 2026-01-01

Over a maximum follow-up of 26 years, the median time to event was 1·2 years (IQR 0·2-3·3) in the delirium group and 1·3 years (0·3-3·6) in the control group. 5 key findings →

Design: cohort study Participants: 909 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

✓ Peer-reviewed alzhub usefulness score 61 out of 100. The Lancet 2025-10-01

Total numbers of global DALYs grew 6·1% (95% UI 4·0-8·1), from 2·64 billion (2·46-2·86) in 2010 to 2·80 billion (2·57-3·08) in 2023, but age-standardised DALY rates, which account for population growth and ageing, decreased by 12·6% (11·0-14·1), revealing large long-term health improvements. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

FDG-PET brain glucose hypometabolism predicts Alzheimer's disease progression pathways in cognitively normal adults: A longitudinal competing risks modeling

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Metabolism Open 2025-09-27

Four progression pathways were concluded from our analyses, cognitive stability (32.8 %), sequential MCI-only decline (34.9 %), accelerated MCI-to-dementia progression (15.8 %), and rapid direct conversion (16.5 %). 5 key findings →

Design: longitudinal study Participants: 1,136 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2018-05-24

Although Aβ did not differ by sex, cognitive decline was greater in females with higher Aβ. 3 key findings →

Participants: 755 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neural biomarker diagnosis and prediction to mild cognitive impairment and Alzheimer's disease using EEG technology

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's research & therapy 2023-02-10

Our study indicates that EEG can be used as a useful screening tool for the diagnosis and disease progression evaluation of MCI and AD. 2 key findings →

Participants: 890 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Neurobiology of aging 2016-01-11

Reduction in hippocampal and amygdala volume measured via structural magnetic resonance imaging is an early marker of Alzheimer's disease (AD). 4 key findings →

Design: case-control study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The frontotemporal dementia-motor neuron disease continuum

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Lancet (London, England) 2016-03-14

Early reports of cognitive and behavioural deficits in motor neuron disease might have been overlooked initially, but the concept of a frontotemporal dementia-motor neuron disease continuum has emerged during the past decade. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Generational Differences in Age-Specific Dementia Prevalence Rates

✓ Peer-reviewed alzhub usefulness score 55 out of 100. JAMA Network Open 2025-06-02

In this cross-sectional study examining generational differences in age-specific dementia prevalence across the US, Europe, and England, we found that individuals from more recent birth cohorts had lower proportions of people with dementia. 4 key findings →

Design: cross-sectional Participants: 62,437 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Potentially Inappropriate Prescribing in Australian Nursing Home Residents with Advanced Dementia: A Substudy of the IDEAL Study

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Journal of palliative medicine 2018-08-14

Use of potentially inappropriate medications in Australian nursing home residents with advanced dementia is common. 3 key findings →

Design: randomized controlled trial Participants: 65 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed